BIONTECH SE SPON. ADRS 1
Commented by Carsten Mainitz on July 13th, 2021 | 07:55 CEST
BioNTech, Defence Therapeutics, Formycon - Which biotech stock suits which investor?
Corona is and remains the threat of the hour. In this respect, it is not surprising that the papers of the German vaccine pioneer BioNTech have gone on a fabulous journey. Other companies are still trying to jump on this bandwagon, too. For example, both Canada's Defence Therapeutics and Munich-based Formycon AG are researching a Covid-19 vaccine. However, these developments are at very different stages. In addition, the further product spectrum differs significantly in some cases. But which share is the right one for the portfolio? We took a closer look at the three dissimilar siblings.
Read
Commented by Stefan Feulner on July 8th, 2021 | 13:18 CEST
BioNTech, Defence Therapeutics, Moderna - The wheel keeps turning
After a hesitant start, Germany is making good progress with vaccinations. Around 47.5 million people, or 57.1% of the total population, have been vaccinated at least once. The number of fully vaccinated people rises to 39.9%. Rosy prospects for the summer in the republic. But now comes the Delta variant. According to initial studies, it is more resistant to the vaccines currently on the market than other variants. Research is continuing, and new manufacturers are entering the market to participate in the billion-dollar business.
Read
Commented by André Will-Laudien on July 6th, 2021 | 13:49 CEST
Defence Therapeutics, CureVac, BioNTech - Successful therapy, earn billions!
Since we have a large number of health-threatening issues on the table, there are just as many biotech and pharma companies that have taken up the cause of researching and combating them. Many of them are publicly traded or in the early stages of venture funding. Investors are spoiled for choice; besides good analysis, they need a fair amount of intuition and luck to find the right stock that will truly become a 500-percenter. The cancer research company CEL-SCI recently disappointed, as did the COVID vaccine expert CureVac - both shares ended in a price disaster. The question remains - which horses are the right ones?
Read
Commented by Armin Schulz on June 30th, 2021 | 12:07 CEST
SAP, Barsele Minerals, BioNTech - Shares have no alternative
The USA is expecting growth of 7% this year and Germany is expected to grow by 3.7%. This growth is above the currently expected inflation. As an investor, you should not be afraid of 2023, even if the FED wants to raise interest rates twice by then. One can confidently assume that interest rates will rise marginally from this historically low level, and that, in turn, is a sign of economies with growth prospects. In addition, the boom in equities could last much longer due to major changes such as e-mobility, climate neutrality and the like. In times of significant changes such as industrialization, there were long-lasting bull markets in equities. Since bonds are still hardly yielding any returns, equities remain highly attractive.
Read
Commented by André Will-Laudien on June 18th, 2021 | 12:49 CEST
CureVac, BioNTech, Novavax, XPhyto Therapeutics - The Covid giants and the sellout!
How quickly the tide can turn in the environment of the Corona pandemic can be seen in the vaccine manufacturers and test providers. BioNTech's share price has been rising steadily since the start of the vaccination campaign in Germany, and minor reports of potential side effects are hardly disturbing. In the case of test provider NanoRepro, the bull market of recent months is turning into a total sell-off, with the share losing over 70%. And then there is the Tübingen-based biotech Company CureVac. Delays in approval and a shock on efficacy send the share down by a whole 50% in one day. We take a closer look at the situation.
Read
Commented by Armin Schulz on June 7th, 2021 | 11:06 CEST
QMines, BioNTech, Beyond Meat - Stock pearls with a lot of potential
Commodity prices are rising, Corona is still a major theme and stock gambles, like AMC last week, are still working. As a resourceful investor, you have to do your research and ideally get an information edge over other investors. If you read a lot, you learn a lot and can often profit from it. Today we have picked out three stocks with a lot of potential - one from the commodities sector, another the Corona flagship and a chance on the next AMC.
Read
Commented by Nico Popp on June 1st, 2021 | 10:05 CEST
Defence Therapeutics, CureVac, BioNTech: Vaccine against cancer makes progress
Biotechnology is the map to the holy grail that needs to be found as quickly as possible for many sick people. When the pandemic broke out last year, it accelerated some developments. For example, mRNA technology, which BioNTech and CureVac had already been researching, was successfully launched as a vaccine technology. It is well known that this can be used to develop effective vaccines against coronaviruses and target diseases such as cancer. BioNTech has this option in mind and holds good cards to succeed with it. The young biotech startup Defence Therapeutics has also recently reported its first successes in the fight against cancer.
Read
Commented by Nico Popp on May 26th, 2021 | 08:15 CEST
BioNTech, PsyBio, Bayer: The opportunities of tomorrow
Even after the pandemic, there will be no "business as usual" in the healthcare system, as shown by a survey conducted a few months ago by the Barmer Institute for Health Research. The scientists surveyed called for far-reaching reforms. In addition to billing and uniform rules, digitization could also be a key to meaningful reforms. Innovative drugs also play a role when it comes to treating Covid-19 and concomitant diseases.
Read
Commented by Carsten Mainitz on May 4th, 2021 | 09:52 CEST
SYNLAB, PsyBio Therapeutics, BioNTech - A newcomer, an up-and-comer and a high-flyer in the big world of pharmaceuticals
Last Friday, laboratory services provider SYNLAB made its stock market debut but had difficulty convincing investors of the sustainability of its current order boom. It is not known whether the issue price led to depressive moods among existing shareholders. If it has, they could be helped by the LSD-related psychoactive ingredients of the American biotech pioneer PsyBio, which are expected to expand and improve treatment options for depression, anxiety and drug addiction in the future. For the BioNTech board members, there should be no risk of depression at present. Instead, one can assume that they are thinking about laying a direct line to a champagne producer. It would at least be deserved.
Read
Commented by Nico Popp on May 3rd, 2021 | 07:25 CEST
BioNTech, CureVac, Cardiol Therapeutics: In on the next blockbuster from the start
The two German companies BioNTech and CureVac, have been causing quite a stir since the outbreak of the pandemic. At first, the biotech newcomers were known only to hard-nosed investors who are used to seizing long-term opportunities and accepting initial uncertainty to do so. Even during the first months of the pandemic, it was far from clear whether BioNTech and CureVac would be successful. Only a few insiders had the right instinct early on thanks to the necessary background knowledge and are pleased with BioNTech's annual performance of 260%. But what characterizes the success of innovative biotech companies? And where are the next opportunities lurking? We outline some exciting investment stories.
Read